Docetaxel Versus Oxaliplatin as Addition to S-1 for Stage II / III Gastric Adenocarcinoma

• Status: Recruiting
• Trial end date: 2025-09-01
• Target enrollment: 0
• Participant gender: All

Summary

S-1 plus oxaliplatin has been proved better than S-1 alone for stage II or III gastric cancer.

Docetaxel also showed excellent efficacy with S-1 in the postoperative setting for stage III gastric cancer.

This trial is designed to investigate the efficacy and safety of S-1 plus docetaxel versus S-1 plus oxalipltin as adjuvant chemotherapy after D2 resection in stage II / III gastric cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
• Treatments: Docetaxel; Oxaliplatin

Criteria

Inclusion Criteria:

• informed consensus of patients

• be able to receive oral administration

• from 18 to 75 years old

• be proven to be primary adenocarcinoma of stomach and staged II or III by pathological evidences

• without other chemotherapy and/or radiation against to the disease

• normal function of other organs including heart,liver ,kidney and so on

• Eastern Cooperative Oncology Group performance status:0~2

Exclusion Criteria:

• history of other malignancy

• allergic reaction to S-1 or oxaliplatin of docetaxel

• be enrolling in other clinical trials

• abnormal GI tract function

• dysfunction of other organs

• female in pregnancy or lactation,or refuse to receive Contraception measures during chemotherapy

• other situation to be judged not adaptive to the study by investigators